FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:2189-2194 November 22, 2007 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Supplementary Material Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Medical research relies on clinical trials to assess therapeutic benefits. Because of the effort and cost involved in these studies, investigators frequently use analyses of subgroups of study participants to extract as much information as possible. Such analyses, which assess the heterogeneity of treatment effects in subgroups of patients, may provide useful information for the care of patients and for future research. However, subgroup analyses also introduce analytic challenges and can lead to overstated and misleading results.^{1,2,3,4,5,6,7} This report outlines the challenges associated with conducting and reporting subgroup analyses, and it sets forth guidelines for their use in the Journal. . . [Full Text of this Article]

Subgroup Analyses and Related Concepts

Subgroup Analysis

Heterogeneity and Statistical Interactions

Multiplicity

Prespecified Analysis versus Post Hoc Analysis

Subgroup Analyses in the Journal — Assessment of Reporting Practices

Analysis of Our Findings and Guidelines for Reporting Subgroups

Guidelines for Reporting Subgroup Analysis.

Related Letters:

Subgroup Analyses in Clinical Trials
Proestel S., Kent D., Hayward R., Wang R., Lagakos S. W., Drazen J. M.
Extract | Full Text | PDF  
N Engl J Med 2008; 358:1199-1200, Mar 13, 2008. Correspondence

More on Subgroup Analyses in Clinical Trials
Pocock S. J., Lubsen J., Wang R., Lagakos S. W.
Extract | Full Text | PDF  
N Engl J Med 2008; 358:2076-2077, May 8, 2008. Correspondence

This article has been cited by other articles:

• Di Bisceglie, A. M., Shiffman, M. L., Everson, G. T., Lindsay, K. L., Everhart, J. E., Wright, E. C., Lee, W. M., Lok, A. S., Bonkovsky, H. L., Morgan, T. R., Ghany, M. G., Morishima, C., Snow, K. K., Dienstag, J. L., the HALT-C Trial Investigators, (2008). Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon. NEJM 359: 2429-2441 [Abstract] [Full Text]  
• Morris, B. H., Oh, W., Tyson, J. E., Stevenson, D. K., Phelps, D. L., O'Shea, T. M., McDavid, G. E., Perritt, R. L., Van Meurs, K. P., Vohr, B. R., Grisby, C., Yao, Q., Pedroza, C., Das, A., Poole, W. K., Carlo, W. A., Duara, S., Laptook, A. R., Salhab, W. A., Shankaran, S., Poindexter, B. B., Fanaroff, A. A., Walsh, M. C., Rasmussen, M. R., Stoll, B. J., Cotten, C. M., Donovan, E. F., Ehrenkranz, R. A., Guillet, R., Higgins, R. D., the NICHD Neonatal Research Network, (2008). Aggressive vs. Conservative Phototherapy for Infants with Extremely Low Birth Weight. NEJM 359: 1885-1896 [Abstract] [Full Text]  
• Bochud, P.-Y., Chien, J. W., Marr, K. A., Leisenring, W. M., Upton, A., Janer, M., Rodrigues, S. D., Li, S., Hansen, J. A., Zhao, L. P., Aderem, A., Boeckh, M. (2008). Toll-like Receptor 4 Polymorphisms and Aspergillosis in Stem-Cell Transplantation. NEJM 359: 1766-1777 [Abstract] [Full Text]  
• Seigel, D., Herm, R. J., Jager, R. D., Mieler, W. F., Miller, J. W. (2008). Age-related macular degeneration.. NEJM 359: 1735-1736 [Full Text]  
• Fatkenheuer, G., Nelson, M., Lazzarin, A., Konourina, I., Hoepelman, A. I.M., Lampiris, H., Hirschel, B., Tebas, P., Raffi, F., Trottier, B., Bellos, N., Saag, M., Cooper, D. A., Westby, M., Tawadrous, M., Sullivan, J. F., Ridgway, C., Dunne, M. W., Felstead, S., Mayer, H., van der Ryst, E., the MOTIVATE 1 and MOTIVATE 2 Study Teams, (2008). Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection. NEJM 359: 1442-1455 [Abstract] [Full Text]  
• Tribble, C. G. (2008). Industry-Sponsored Negative Trials and the Potential Pitfalls of Post Hoc Analysis. Arch Surg 143: 933-934 [Full Text]  
• Paulussen, M., Craft, A. W., Lewis, I., Hackshaw, A., Douglas, C., Dunst, J., Schuck, A., Winkelmann, W., Kohler, G., Poremba, C., Zoubek, A., Ladenstein, R., van den Berg, H., Hunold, A., Cassoni, A., Spooner, D., Grimer, R., Whelan, J., McTiernan, A., Jurgens, H. (2008). Results of the EICESS-92 Study: Two Randomized Trials of Ewing's Sarcoma Treatment--Cyclophosphamide Compared With Ifosfamide in Standard-Risk Patients and Assessment of Benefit of Etoposide Added to Standard Treatment in High-Risk Patients. JCO 26: 4385-4393 [Abstract] [Full Text]  
• Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., Erfan, J., Zabolotnyy, D., Kienzer, H.-R., Cupissol, D., Peyrade, F., Benasso, M., Vynnychenko, I., De Raucourt, D., Bokemeyer, C., Schueler, A., Amellal, N., Hitt, R. (2008). Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer. NEJM 359: 1116-1127 [Abstract] [Full Text]  
• Ellison, G. T. H., Kaufman, J. S., Head, R. F., Martin, P. A., Kahn, J. D. (2008). Flaws in the U.S. Food and Drug Administration's Rationale for Supporting the Development and Approval of BiDil as a Treatment for Heart Failure Only in Black Patients.. J Law Med Ethics 36: 449-457  
• Kastrati, A., Neumann, F.-J., Mehilli, J., Byrne, R. A., Iijima, R., Buttner, H. J., Khattab, A. A., Schulz, S., Blankenship, J. C., Pache, J., Minners, J., Seyfarth, M., Graf, I., Skelding, K. A., Dirschinger, J., Richardt, G., Berger, P. B., Schomig, A., the ISAR-REACT 3 Trial Investigators, (2008). Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention. NEJM 359: 688-696 [Abstract] [Full Text]  
• Cooper, D. A., Steigbigel, R. T., Gatell, J. M., Rockstroh, J. K., Katlama, C., Yeni, P., Lazzarin, A., Clotet, B., Kumar, P. N., Eron, J. E., Schechter, M., Markowitz, M., Loutfy, M. R., Lennox, J. L., Zhao, J., Chen, J., Ryan, D. M., Rhodes, R. R., Killar, J. A., Gilde, L. R., Strohmaier, K. M., Meibohm, A. R., Miller, M. D., Hazuda, D. J., Nessly, M. L., DiNubile, M. J., Isaacs, R. D., Teppler, H., Nguyen, B.-Y., the BENCHMRK Study Teams, (2008). Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection. NEJM 359: 355-365 [Abstract] [Full Text]  
• Gueugniaud, P.-Y., David, J.-S., Chanzy, E., Hubert, H., Dubien, P.-Y., Mauriaucourt, P., Braganca, C., Billeres, X., Clotteau-Lambert, M.-P., Fuster, P., Thiercelin, D., Debaty, G., Ricard-Hibon, A., Roux, P., Espesson, C., Querellou, E., Ducros, L., Ecollan, P., Halbout, L., Savary, D., Guillaumee, F., Maupoint, R., Capelle, P., Bracq, C., Dreyfus, P., Nouguier, P., Gache, A., Meurisse, C., Boulanger, B., Lae, C., Metzger, J., Raphael, V., Beruben, A., Wenzel, V., Guinhouya, C., Vilhelm, C., Marret, E. (2008). Vasopressin and Epinephrine vs. Epinephrine Alone in Cardiopulmonary Resuscitation. NEJM 359: 21-30 [Abstract] [Full Text]  
• WALKER, E., HERNANDEZ, A. V., KATTAN, M. W. (2008). Meta-analysis: Its strengths and limitations. Cleveland Clinic Journal of Medicine 75: 431-439 [Abstract] [Full Text]  
• Pocock, S. J, Travison, T. G, Wruck, L. M (2008). How to interpret figures in reports of clinical trials. BMJ 336: 1166-1169 [Full Text]  
• Pocock, S. J., Lubsen, J., Wang, R., Lagakos, S. W. (2008). More on Subgroup Analyses in Clinical Trials. NEJM 358: 2076-2077 [Full Text]  
• Brasher, P. M.A., Brant, R. F. (2008). Problems of multiplicity/Problemes de multiplicite. Canadian J. Anesthesia 55: 259-264 [Full Text]  
• Ramalingam, S. S., Dahlberg, S. E., Gray, R., Langer, C. J., Belani, C. P., Brahmer, J. R., Sandler, A. B., Schiller, J. H., Johnson, D. H. (2008). Meaningful Subset Analyses Contribute to Optimal Patient Care. JCO 26: 2064-2065 [Full Text]  
• Proestel, S., Kent, D., Hayward, R., Wang, R., Lagakos, S. W., Drazen, J. M. (2008). Subgroup analyses in clinical trials.. NEJM 358: 1199-1199 [Full Text]